News

Events

2025/03 - Exonox Biosciences signs collaboration agreement with Graphen Drugomics, an AI drug development company, to develop exosome biomarkers for the early detection and progression of triple-negative breast cancer.
2025/01 - “PROTEIN BIOMARKERS FOR NEPHROPATHY AND APPLICATIONS THEREOF”, this CN patent application is approved for issuance as a patent.
2024/06 - Exonox published poster - "Proteomic landscape of plasma exosome to discovery protein biomarkers of triple-negative breast cancer and to assess therapeutic outcomes in TNBC" at "The 20th Taiwan Society for Mass Spectrometry Annual Conference" in Taiwan. (Outstanding Paper Award)
2024/02 - EU unitary patent certificate: “PROTEIN BIOMARKERS FOR NEPHROPATHY AND APPLICATIONS THEREOF”. Including 17 countries, Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Portugal, Slovenia, Sweden.
2023/09 - Exonox's dual-biomarker diagnostic tool – Exonox® Renal recieved the notice of intention to grant for an EU patent.
2023/07 - Exonox exhibits at "BIO Asia-Taiwan Exhibition" in Taipei Nangang Exhibition Center, Hall 1 on 2023/07/27~2023/07/30. (Booth No: N604).
2023/06 - Exonox Biosciences announces a highly specific exosome-based liquid biopsy for the differential diagnosis of triple-negative breast cancer.
2023/05 - Exonox published poster - "Development of Diagnostic Triple Negative Breast Cancer Exosome Liquid Biopsy" at "National Biotechnology Research Park DEMO DAY" in Taiwan.
2022/10 - Exonox present - "Exosome - Based Therapeutical Solution from RIGHT Targets" at "4th Exosome-based Therapeutic Development Summit " in Boston.
2022/08 - Exonox published poster - “The optimization of plasma exosome proteomics and its application to discovery protein biomarkers of triple-negative breast cancer” at "The 18th Taiwan Society for Mass Spectrometry annual conference”.
2021/09 - Exonox implement and display the D&B D-U-N-S®Registered™. D-U-N-S Number: 65-637-4989
2021/05 - Exonox together with RND Biomedical launch the prototype of dual-biomarker, one-step sandwich ELISA for the detection/diagnosis of early renal injury.
2020/10 - Exonox is invited to present at the “Exosome Diagnosis and Drug Development Technology“ Conference held by BMCC.
2019/07 - Exonox signed a clinical trial contract with NCKU Hospital, Taiwan, to expand the blood sample collection for novel TNBC exosomal biomarker discovery.
2018/12 - Exonox teamed up with RND Biomedical to co-develop an IVD ELISA for early diagnosis of renal injury and diabetic nephropathy.
2018/10 - Exonox established a proprietary Optimized Exosome Isolation/Purification Protocol (human blood sample).
2018/02 - Exonox signed a clinical trial contract with CMU Hospital, Taiwan, to investigate the novel exosomal biomarker in TNBC patients.